![\"\"](\"https:\/\/www.iispv.cat\/wp-content\/uploads\/2025\/02\/18.02.2025_Ajuda-a-Projectes-Estrategics-AECC-2024-2-1024x655.jpeg\")
<\/figure><\/div>\n\n\nThe headquarters of the Association Against Cancer (AECC) in Tarragona was the scene of the ceremony of the 2024 Research Aid to investigate the cancer that will develop in Tarragona. The support for the project of Dr. Matilde Rodr\u00edguez Chac\u00f3n, head of the DIBIOMEC group at the Pere Virgili Health Research Institute in Tarragona (IISPV-CERCA), Research Unit of the Joan XXIII University Hospital in Tarragona, consists of an economic endowment of 150,000\u20ac and will last three years. This project is focused on creating a new tool to predict aggressive prostate cancer, based on how the genetic information contained in the vesicles released by fat around the prostate affects the tumor.<\/p>\n\n\n\n
This research could significantly improve the prognosis of aggressive tumors by allowing earlier and more accurate treatments for patients. This aid, like all those promoted by the Association, has as its main objective to increase survival rate in cancer to exceed 70% by 2030, to improve the treatments received by patients and to improve their quality of life.<\/p>\n\n\n\n
Fede Ad\u00e1n, president of the Association Against Cancer of Tarragona; Dr. Meritxell Arenas, patron of the Scientific Foundation of the Association Against Cancer and director of the Radiotherapy Oncology service of the Sant Joan University Hospital in Reus; the beneficiary researcher, Dr. Matilde Rodr\u00edguez Chac\u00f3n; accompanied by authorities and institutional representatives of the territory were present at the event. This year is the third consecutive year that a grant is granted to a research project in Tarragona. In total, 150,000\u20ac are awarded in a grant that is given with the aim of promoting oncological research in the province of Tarragona, and contributing to increase the average survival rate of people with cancer to 70% by 2030 and, to bring research results closer to patients. Currently, the Association Against Cancer in Tarragona has around 600,000\u20ac for oncological research projects in the province.<\/p>\n\n\n\n
Fede Ad\u00e1n, president of the Association Against Cancer in Tarragona, highlighted \u201cthe entity\u2019s commitment to oncological research and to researchers in the province, in order to provide solutions to the needs of doctors and patients, as well as our commitment to continue financing and giving visibility to oncological research carried out in the territory\u201d.<\/p>\n\n\n\n
Oncological research, a priority<\/strong><\/p>\n\n\n\n Currently in Spain, one case of cancer is diagnosed every 2 minutes. 1 in 2 men and 1 in 3 women will have cancer throughout their lives. Promoting oncological research must therefore be a priority for the whole of society, including governments, companies and institutions.<\/p>\n\n\n\n The AECC 2024 grants cover all phases of the research race, and their strategic lines are: increasing funding with a special focus on low survival rate cancers, attracting research talent to promote job stability for researchers, promoting innovation and clinical research so that results reach the patient and promoting clinical research.<\/p>\n\n\n\n In 2024, the Association Against Cancer awarded 32 million euros in 257 grants in different research projects on different types of cancer.<\/p>\n","protected":false},"excerpt":{"rendered":" The AECC 2024 Strategic Projects Aid has an economic endowment of 150,000\u20ac and a lenght of three years The headquarters of the Association Against Cancer (AECC) in Tarragona was the scene of the ceremony of the 2024 Research Aid to investigate the cancer that will develop in Tarragona. The support for the project of Dr. […]<\/p>\n","protected":false},"author":35,"featured_media":103958,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1883,2165,2072,2073,1477,2074,1026,1831,1478,1479,2092],"tags":[],"class_list":["post-104735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualitat-en","category-agenda-en","category-assistencia-en","category-docencia-i-formacio-en","category-innovacio-en","category-institucional-en","category-noticies-iispv-en","category-press-releases","category-publicacions-en","category-recerca-en","category-temes-de-salut-en"],"_links":{"self":[{"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/posts\/104735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/comments?post=104735"}],"version-history":[{"count":3,"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/posts\/104735\/revisions"}],"predecessor-version":[{"id":104743,"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/posts\/104735\/revisions\/104743"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/media\/103958"}],"wp:attachment":[{"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/media?parent=104735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/categories?post=104735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iispv.cat\/en\/wp-json\/wp\/v2\/tags?post=104735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}